Androgen receptor (AR) positive vs negative roles in prostate cancer cell deaths including apoptosis, anoikis, entosis, necrosis and autophagic cell death

Cancer Treatment Reviews

Volumn 40, Issue 1, 2014, Pages 31-40

  Wen, Simeng ^a,b   Niu, Yuanjie ^a   Lee, Soo Ok ^b   Chang, Chawnshang ^b,c  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Androgen receptor; Anoikis; Apoptosis; Autophagy; Cell death; Entosis; Necrosis; Prostate cancer

Indexed keywords

3 METHYLADENINE; ANDROGEN RECEPTOR; BICALUTAMIDE; BORTEZOMIB; CISPLATIN; CYPROTERONE ACETATE; DOCETAXEL;

ANDROGEN DEPRIVATION THERAPY; ANOIKIS; APOPTOSIS; AUTOPHAGY; BASAL CELL; CANCER CELL; CANCER GROWTH; CANCER STEM CELL; CELL DEATH; CELL DIFFERENTIATION; CELL POPULATION; CELL PROLIFERATION; ENTOSIS; EPITHELIUM CELL; HUMAN; METASTASIS; NECROSIS; PROSTATE CANCER; REVIEW; STROMA CELL;

ANDROGEN RECEPTOR; ANOIKIS; APOPTOSIS; AUTOPHAGY; CELL DEATH; ENTOSIS; NECROSIS; PROSTATE CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; CELL DEATH; CELL PROLIFERATION; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION;

EID: 84887087288     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2013.07.008     Document Type: Review

References (157)

1. Brawley O.W. Trends in prostate cancer in the United States. J Natl Cancer Inst Monogr 2012, 2012:152-156.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics. CA: Cancer J Clin 2013, 63:11-30.
3. Lowe S.W., Cepero E., Evan G. Intrinsic tumour suppression. Nature 2004, 432:307-315.
4. Adams J.M., Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007, 26:1324-1337.
5. Williams G.T. Programmed cell death: apoptosis and oncogenesis. Cell 1991, 65:1097-1098.
6. Johnstone R.W., Ruefli A.A., Lowe S.W. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002, 108:153-164.
7. Chang C.S., Kokontis J., Liao S.T. Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science 1988, 240:324-326.
8. Jenster G. The role of the androgen receptor in the development and progression of prostate cancer. Semin Oncol 1999, 26:407-421.
9. Brinkmann A.O., Blok L.J., de Ruiter P.E., Doesburg P., Steketee K., Berrevoets C.A., et al. Mechanisms of androgen receptor activation and function. J Steroid Biochem Mol Biol 1999, 69:307-313.
10. Chang C., Saltzman A., Yeh S., Young W., Keller E., Lee H.J., et al. Androgen receptor: an overview. Crit Rev Eukaryot Gene Expr 1995, 5:97-125.
11. de Launoit Y., Veilleux R., Dufour M., Simard J., Labrie F. Characteristics of the biphasic action of androgens and of the potent antiproliferative effects of the new pure antiestrogen EM-139 on cell cycle kinetic parameters in LNCaP human prostatic cancer cells. Cancer Res 1991, 51:5165-5170.
12. Huggins C., Hodges C.V. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA 1972, 22:232-240.
13. Niu Y., Chang T.M., Yeh S., Ma W.L., Wang Y.Z., Chang C. Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails. Oncogene 2010, 29:3593-3604.
14. Singer E.A., Golijanin D.J., Messing E.M. Androgen deprivation therapy for advanced prostate cancer: why does it fail and can its effects be prolonged?. Can J Urol 2008, 15:4381-4387.
15. Yeh S., Niu Y., Miyamoto H., Chang T., Chang C. Differential roles of androgen receptor in prostate development and cancer progression. Androgen action in prostate cancer 2009, 73-89. Springer, US. J. Mohler, D. Tindall (Eds.).
16. Denis L.J., Griffiths K. Endocrine treatment in prostate cancer. Semin Surg Oncol 2000, 18:52-74.
17. Eisenberger M.A., Blumenstein B.A., Crawford E.D., Miller G., McLeod D.G., Loehrer P.J., et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998, 339:1036-1042.
18. Schroder F., Crawford E.D., Axcrona K., Payne H., Keane T.E. Androgen deprivation therapy: past, present and future. BJU Int 2012, 109(Suppl. 6):1-12.
19. Pagliarulo V., Bracarda S., Eisenberger M.A., Mottet N., Schroder F.H., Sternberg C.N., et al. Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol 2012, 61:11-25.
20. Niu Y., Altuwaijri S., Yeh S., Lai K.P., Yu S., Chuang K.H., et al. Targeting the stromal androgen receptor in primary prostate tumors at earlier stages. Proc Natl Acad Sci USA 2008, 105:12188-12193.
21. Niu Y., Altuwaijri S., Lai K.P., Wu C.T., Ricke W.A., Messing E.M., et al. Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc Natl Acad Sci USA 2008, 105:12182-12187.
22. Sun Y., Wang B.E., Leong K.G., Yue P., Li L., Jhunjhunwala S., et al. Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy. Cancer Res 2012, 72:527-536.
23. van Bokhoven A., Varella-Garcia M., Korch C., Johannes W.U., Smith E.E., Miller H.L., et al. Molecular characterization of human prostate carcinoma cell lines. Prostate 2003, 57:205-225.
24. van Leenders G.J.L.H., Schalken J.A. Epithelial cell differentiation in the human prostate epithelium: Implications for the pathogenesis and therapy of prostate cancer. Crit Rev Oncol/Hematol 2003, 46:3-10.
25. Bonkhoff H., Stein U., Remberger K. The proliferative function of basal cells in the normal and hyperplastic human prostate. Prostate 1994, 24:114-118.
26. Litvinov I.V., De Marzo A.M., Isaacs J.T. Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling?. J Clin Endocrinol Metab 2003, 88:2972-2982.
27. Tokar E.J., Ancrile B.B., Cunha G.R., Webber M.M. Stem/progenitor and intermediate cell types and the origin of human prostate cancer. Differentiation 2005, 73:463-473.
28. Horoszewicz J.S., Leong S.S., Kawinski E., Karr J.P., Rosenthal H., Chu T.M., et al. LNCaP model of human prostatic carcinoma. Cancer Res 1983, 43:1809-1818.
29. Horoszewicz J.S., Leong S.S., Chu T.M., Wajsman Z.L., Friedman M., Papsidero L., et al. The LNCaP cell line-a new model for studies on human prostatic carcinoma. Prog Clin Biol Res 1980, 37:115-132.
30. Eder I.E., Culig Z., Ramoner R., Thurnher M., Putz T., Nessler-Menardi C., et al. Inhibition of LncaP prostate cancer cells by means of androgen receptor antisense oligonucleotides. Cancer Gene Ther 2000, 7:997-1007.
31. Haag P., Bektic J., Bartsch G., Klocker H., Eder I.E. Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells. J Steroid Biochem Mol Biol 2005, 96:251-258.
32. Liao X., Tang S., Thrasher J.B., Griebling T.L., Li B. Small-interfering RNA-induced androgen receptor silencing leads to apoptotic cell death in prostate cancer. Mol Cancer Ther 2005, 4:505-515.
33. Nagabhushan M., Miller C.M., Pretlow T.P., Giaconia J.M., Edgehouse N.L., Schwartz S., et al. CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Res 1996, 56:3042-3046.
34. Li T.H., Zhao H., Peng Y., Beliakoff J., Brooks J.D., Sun Z. A promoting role of androgen receptor in androgen-sensitive and -insensitive prostate cancer cells. Nucleic Acids Res 2007, 35:2767-2776.
35. Kaighn M.E., Narayan K.S., Ohnuki Y., Lechner J.F., Jones L.W. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979, 17:16-23.
36. Litvinov I.V., Chang C., Isaacs J.T. Molecular characterization of the commonly used human androgen receptor expression vector, pSG5-AR. Prostate 2004, 58:319-324.
37. Litvinov I.V., Antony L., Dalrymple S.L., Becker R., Cheng L., Isaacs J.T. PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor. Prostate 2006, 66:1329-1338.
38. Lee S.O., Tian J., Huang C.K., Ma Z., Lai K.P., Hsiao H., et al. Suppressor role of androgen receptor in proliferation of prostate basal epithelial and progenitor cells. J Endocrinol 2012, 213:173-182.
39. Cunha G.R., Hayward S.W., Wang Y.Z., Ricke W.A. Role of the stromal microenvironment in carcinogenesis of the prostate. Int J Cancer 2003, 107:1-10.
40. Bhowmick N.A., Moses H.L. Tumor-stroma interactions. Curr Opin Genet Dev 2005, 15:97-101.
41. Condon M.S. The role of the stromal microenvironment in prostate cancer. Semin Cancer Biol 2005, 15:132-137.
42. Halin S., Hammarsten P., Wikstrom P., Bergh A. Androgen-insensitive prostate cancer cells transiently respond to castration treatment when growing in an androgen-dependent prostate environment. Prostate 2007, 67:370-377.
43. Gleave M., Hsieh J.T., Gao C.A., von Eschenbach A.C., Chung L.W. Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res 1991, 51:3753-3761.
44. Lai K.P., Yamashita S., Vitkus S., Shyr C.R., Yeh S., Chang C. Suppressed prostate epithelial development with impaired branching morphogenesis in mice lacking stromal fibromuscular androgen receptor. Mol Endocrinol 2012, 26:52-66.
45. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
46. Kaarbo M., Klokk T.I., Saatcioglu F. Androgen signaling and its interactions with other signaling pathways in prostate cancer. BioEssays 2007, 29:1227-1238.
47. Lin Y., Kokontis J., Tang F., Godfrey B., Liao S., Lin A., et al. Androgen and its receptor promote Bax-mediated apoptosis. Mol Cell Biol 2006, 26:1908-1916.
48. Tang F., Kokontis J., Lin Y., Liao S., Lin A., Xiang J. Androgen via p21 inhibits tumor necrosis factor alpha-induced JNK activation and apoptosis. J Biol Chem 2009, 284:32353-32358.
49. Bhatnagar N., Li X., Padi S.K., Zhang Q., Tang M.S., Guo B. Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells. Cell Death Dis 2010, 1:e105.
50. Flourakis M., Lehen'kyi V., Beck B., Raphael M., Vandenberghe M., Abeele F.V., et al. Orai1 contributes to the establishment of an apoptosis-resistant phenotype in prostate cancer cells. Cell Death Dis 2010, 1:e75.
51. Bennett H.L., Fleming J.T., O'Prey J., Ryan K.M., Leung H.Y. Androgens modulate autophagy and cell death via regulation of the endoplasmic reticulum chaperone glucose-regulated protein 78/BiP in prostate cancer cells. Cell Death Dis 2010, 1:e72.
52. Rokhlin O.W., Taghiyev A.F., Guseva N.V., Glover R.A., Chumakov P.M., Kravchenko J.E., et al. Androgen regulates apoptosis induced by TNFR family ligands via multiple signaling pathways in LNCaP. Oncogene 2005, 24:6773-6784.
53. Jiang Q., Yeh S., Wang X., Xu D., Zhang Q., Wen X., et al. Targeting androgen receptor leads to suppression of prostate cancer via induction of autophagy. J Urol 2012, 188:1361-1368.
54. Ma W.L., Hsu C.L., Yeh C.C., Wu M.H., Huang C.K., Jeng L.B., et al. Hepatic androgen receptor suppresses hepatocellular carcinoma metastasis through modulation of cell migration and anoikis. Hepatology 2012, 56:176-185.
55. Bhuiyan M.M., Li Y., Banerjee S., Ahmed F., Wang Z., Ali S., et al. Down-regulation of androgen receptor by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells. Cancer Res 2006, 66:10064-10072.
56. Oh S.J., Erb H.H., Hobisch A., Santer F.R., Culig Z. Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways. Endocrine Relat Cancer 2012, 19:305-319.
57. Tang Y., Li X., Liu Z., Simoneau A.R., Xie J., Flavokawain Zi.X., et al. A kava chalcone, induces apoptosis via up-regulation of death-receptor 5 and Bim expression in androgen receptor negative, hormonal refractory prostate cancer cell lines and reduces tumor growth. Int J Cancer J 2010, 127:1758-1768.
58. Han H., Qiu L., Wang X., Qiu F., Wong Y., Yao X. Physalins A and B inhibit androgen-independent prostate cancer cell growth through activation of cell apoptosis and downregulation of androgen receptor expression. Biol Pharm Bull 2011, 34:1584-1588.
59. Galluzzi L., Vitale I., Abrams J.M., Alnemri E.S., Baehrecke E.H., Blagosklonny M.V., et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ 2012, 19:107-120.
60. Lewis E.M., Wilkinson A.S., Jackson J.S., Mehra R., Varambally S., Chinnaiyan A.M., et al. The enzymatic activity of apoptosis-inducing factor supports energy metabolism benefiting the growth and invasiveness of advanced prostate cancer cells. J Biol Chem 2012, 287:43862-43875.
61. Carraway R.E., Dobner P.R. Zinc pyrithione induces ERK- and PKC-dependent necrosis distinct from TPEN-induced apoptosis in prostate cancer cells. Biochim Biophys Acta 2012, 1823:544-557.
62. Liu Z. The initial observation that AR inhibits prostate cancer cell necrosis: Tianjin Medical University 2012, Tianjin, China.
63. Ouyang D.Y., Xu L.H., He X.H., Zhang Y.T., Zeng L.H., Cai J.Y., et al. Autophagy is differentially induced in prostate cancer LNCaP, DU145 and PC-3 cells via distinct splicing profiles of ATG5. Autophagy 2013, 9:20-32.
64. Giannoni E., Fiaschi T., Ramponi G., Chiarugi P. Redox regulation of anoikis resistance of metastatic prostate cancer cells: key role for Src and EGFR-mediated pro-survival signals. Oncogene 2009, 28:2074-2086.
65. Wen S., Shang Z., Zhu S., Chang C., Niu Y. Androgen receptor enhances entosis, a non-apoptotic cell death, through modulation of Rho/ROCK pathway in prostate cancer cells. Prostate 2013, 73:1306-1315.
66. Frezza M., Yang H., Dou Q.P. Modulation of the tumor cell death pathway by androgen receptor in response to cytotoxic stimuli. J Cell Physiol 2011, 226:2731-2739.
67. Bennett H.L., Stockley J., Fleming J.T., Mandal R., O'Prey J., Ryan K.M., et al. Does androgen-ablation therapy(AAT) associated autophagy have a pro-survival effect in LNCaP human prostate cancer cells?. BJU Int 2013, 111:672-682.
68. Lin T.H., Lee S.O., Niu Y., Xu D., Liang L., Li L., et al. Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/enzalutamide versus anti-androgen receptor ASC-J9(R) lead to promotion versus suppression of prostate cancer metastasis. J Biol Chem 2013, 288:19359-19369.
69. Kerr J.F., Wyllie A.H., Currie A.R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972, 26:239-257.
70. Fulda S., Debatin K.M. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006, 25:4798-4811.
71. Fulda S., Debatin K.M. Modulation of apoptosis signaling for cancer therapy. Arch Immunol Ther Exp 2006, 54:173-175.
72. Pipan N., Sterle M. Cytochemical analysis of organelle degradation in phagosomes and apoptotic cells of the mucoid epithelium of mice. Histochemistry 1979, 59:225-232.
73. Thornberry N.A., Bull H.G., Calaycay J.R., Chapman K.T., Howard A.D., Kostura M.J., et al. A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature 1992, 356:768-774.
74. Thornberry N.A., Lazebnik Y. Caspases: enemies within. Science 1998, 281(5381):5.
75. Degterev A., Boyce M., Yuan J. A decade of caspases. Oncogene 2003, 22:8543-8567.
76. Hengartner M.O. The biochemistry of apoptosis. Nature 2000, 407:770-776.
77. Hengartner M.O. The biochemistry of apoptosis. Nature 2000, 407(6805):7.
78. Cory S., Adams J.M. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002, 2:647-656.
79. Godfrey B., Lin Y., Larson J., Haferkamp B., Xiang J. Proteasomal degradation unleashes the pro-death activity of androgen receptor. Cell Res 2010, 20:1138-1147.
80. Li R.J., Qiu S.D., Wang H.X., Tian H., Wang L.R., Huo Y.W. Androgen receptor: a new player associated with apoptosis and proliferation of pancreatic beta-cell in type 1 diabetes mellitus. Apoptosis 2008, 13:959-971.
81. Williams G.T., Smith C.A. Molecular regulation of apoptosis: genetic controls on cell death. Cell 1993, 74:777-779.
82. Matsumoto T., Sakari M., Okada M., Yokoyama A., Takahashi S., Kouzmenko A., et al. The androgen receptor in health and disease. Annu Rev Physiol 2013, 75:201-224.
83. Gorospe M., Cirielli C., Wang X., Seth P., Capogrossi M.C., Holbrook N.J. P21(Waf1/Cip1) protects against p53-mediated apoptosis of human melanoma cells. Oncogene 1997, 14:929-935.
84. Asada M., Yamada T., Ichijo H., Delia D., Miyazono K., Fukumuro K., et al. Apoptosis inhibitory activity of cytoplasmic p21Cip1/WAF1 in monocytic differentiation. EMBO J 1999, 18(5):12.
85. Lu S., Liu M., Epner D.E., Tsai S.Y., Tsai M.J. Androgen regulation of the cyclin-dependent kinase inhibitor p21 gene through an androgen response element in the proximal promoter. Mol Endocrinol 1999, 13:376-384.
86. Kimura K., Markowski M., Bowen C., Gelmann E.P. Androgen blocks apoptosis of hormone-dependent prostate cancer cells. Cancer Res 2001, 61:5611-5618.
87. Kadowaki Y., Chari N.S., Teo A.E., Hashi A., Spurgers K.B., McDonnell T.J. PI3 Kinase inhibition on TRAIL-induced apoptosis correlates with androgen-sensitivity and p21 expression in prostate cancer cells. Apoptosis 2011, 16:627-635.
88. Sun M., Yang L., Feldman R.I., Sun X.M., Bhalla K.N., Jove R., et al. Activation of phosphatidylinositol 3-kinase/Akt pathway by androgen through interaction of p85alpha, androgen receptor, and Src. J Biol Chem 2003, 278:42992-43000.
89. Yang L., Xie S., Jamaluddin M.S., Altuwaijri S., Ni J., Kim E., et al. Induction of androgen receptor expression by phosphatidylinositol 3-kinase/Akt downstream substrate, FOXO3a, and their roles in apoptosis of LNCaP prostate cancer cells. J Biol Chem 2005, 280:33558-33565.
90. Nguyen T.V., Yao M., Pike C.J. Androgens activate mitogen-activated protein kinase signaling: role in neuroprotection. J Neurochem 2005, 94:1639-1651.
91. Simoes V.L., Alves M.G., Martins A.D., Dias T.R., Rato L., Socorro S., et al. Regulation of apoptotic signaling pathways by 5alpha-dihydrotestosterone and 17beta-estradiol in immature rat Sertoli cells. J Steroid Biochem Mol Biol 2013, 135:15-23.
92. Brooke G.N., Culley R.L., Dart D.A., Mann D.J., Gaughan L., McCracken S.R., et al. FUS/TLS is a novel mediator of androgen-dependent cell-cycle progression and prostate cancer growth. Cancer Res 2011, 71:914-924.
93. Diallo J.S., Peant B., Lessard L., Delvoye N., Le Page C., Mes-Masson A.M., et al. An androgen-independent androgen receptor function protects from inositol hexakisphosphate toxicity in the PC3/PC3(AR) prostate cancer cell lines. Prostate 2006, 66:1245-1256.
94. Yang H., Murthy S., Sarkar F.H., Sheng S., Reddy G.P., Dou Q.P. Calpain-mediated androgen receptor breakdown in apoptotic prostate cancer cells. J Cell Physiol 2008, 217:569-576.
95. Lin Y., Lu Z., Kokontis J., Xiang J. Androgen receptor primes prostate cancer cells to apoptosis through down-regulation of basal p21 expression. Biochem Biophys Res Commun 2013, 430:289-293.
96. Risek B., Bilski P., Rice A.B., Schrader W.T. Androgen receptor-mediated apoptosis is regulated by photoactivatable androgen receptor ligands. Mol Endocrinol 2008, 22:2099-2115.
97. LaFevre-Bernt M.A., Ellerby L.M. Kennedy's disease. Phosphorylation of the polyglutamine-expanded form of androgen receptor regulates its cleavage by caspase-3 and enhances cell death. J Biol Chem 2003, 278:34918-34924.
98. Young J.E., Garden G.A., Martinez R.A., Tanaka F., Sandoval C.M., Smith A.C., et al. Polyglutamine-expanded androgen receptor truncation fragments activate a Bax-dependent apoptotic cascade mediated by DP5/Hrk. J Neurosci 2009, 29:1987-1997.
99. Hatzoglou A., Kampa M., Kogia C., Charalampopoulos I., Theodoropoulos P.A., Anezinis P., et al. Membrane androgen receptor activation induces apoptotic regression of human prostate cancer cells in vitro and in vivo. J Clin Endocrinol Metab 2005, 90:893-903.
100. Papadopoulou N., Charalampopoulos I., Anagnostopoulou V., Konstantinidis G., Foller M., Gravanis A., et al. Membrane androgen receptor activation triggers down-regulation of PI-3K/Akt/NF-kappaB activity and induces apoptotic responses via Bad, FasL and caspase-3 in DU145 prostate cancer cells. Molecular Cancer 2008, 7:88.
101. Adams J.C., Watt F.M. Regulation of development and differentiation by the extracellular matrix. Development 1993, 117:1183-1198.
102. Blau H.M., Baltimore D. Differentiation requires continuous regulation. J Cell Biol 1991, 112:781-783.
103. Takeuchi T., Suzuki M., Kumagai J., Kamijo T., Sakai M., Kitamura T. Extracellular matrix dermatopontin modulates prostate cell growth in vivo. J Endocrinol 2006, 190:351-361.
104. Ruoslahti E., Reed J.C. Anchorage dependence, integrins, and apoptosis. Cell 1994, 77:477-478.
105. Frisch S.M., Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 1994, 124:619-626.
106. Rennebeck G., Martelli M., Kyprianou N. Anoikis and survival connections in the tumor microenvironment: is there a role in prostate cancer metastasis?. Cancer Res 2005, 65:11230-11235.
107. Keledjian K., Kyprianou N. Anoikis induction by quinazoline based alpha 1-adrenoceptor antagonists in prostate cancer cells: antagonistic effect of bcl-2. J Urol 2003, 169:1150-1156.
108. Garrison J.B., Kyprianou N. Novel targeting of apoptosis pathways for prostate cancer therapy. Curr Cancer Drug Targets 2004, 4:85-95.
109. Frisch S.M., Ruoslahti E. Integrins and anoikis. Curr Opin Cell Biol 1997, 9:701-706.
110. Frisch S.M., Screaton R.A. Anoikis mechanisms. Curr Opin Cell Biol 2001, 13:555-562.
111. Reginato M.J., Mills K.R., Paulus J.K., Lynch D.K., Sgroi D.C., Debnath J., et al. Integrins and EGFR coordinately regulate the pro-apoptotic protein Bim to prevent anoikis. Nat Cell Biol 2003, 5:733-740.
112. Mailleux A.A., Overholtzer M., Schmelzle T., Bouillet P., Strasser A., Brugge J.S. BIM regulates apoptosis during mammary ductal morphogenesis, and its absence reveals alternative cell death mechanisms. Dev Cell 2007, 12:221-234.
113. Sakamoto S., Kyprianou N. Targeting anoikis resistance in prostate cancer metastasis. Mol Aspects Med 2010, 31:205-214.
114. Wen H.C., Avivar-Valderas A., Sosa M.S., Girnius N., Farias E.F., Davis R.J., et al. p38alpha signaling induces anoikis and lumen formation during mammary morphogenesis. Sci Signal 2011, 4:ra34.
115. Chun J., Joo E.J., Kang M., Kim Y.S. Platycodin D induces anoikis and caspase-mediated apoptosis via p38 MAPK in AGS human gastric cancer cells. J Cell Biochem 2013, 114:456-470.
116. Overholtzer M., Mailleux A.A., Mouneimne G., Normand G., Schnitt S.J., King R.W., et al. A nonapoptotic cell death process, entosis, that occurs by cell-in-cell invasion. Cell 2007, 131:966-979.
117. White E. Entosis: it's a cell-eat-cell world. Cell 2007, 131:840-842.
118. Ohsaki H., Haba R., Matsunaga T., Nakamura M., Kiyomoto H., Hirakawa E. 'Cannibalism' (cell phagocytosis) does not differentiate reactive renal tubular cells from urothelial carcinoma cells. Cytopathology 2009, 20:224-230.
119. Xia P., Wang S., Guo Z., Yao X. Emperipolesis, entosis and beyond: dance with fate. Cell Res 2008, 18:705-707.
120. Yang Y.Q., Li J.C. Progress of research in cell-in-cell phenomena. Anal Rec (Hoboken) 2012, 295:372-377.
121. Krajcovic M., Johnson N.B., Sun Q., Normand G., Hoover N., Yao E., et al. A non-genetic route to aneuploidy in human cancers. Nat Cell Biol 2011, 13:324-330.
122. Janssen A., Medema R.H. Entosis: aneuploidy by invasion. Nat Cell Biol 2011, 13:199-201.
123. Fiorentini C., Falzano L., Fabbri A., Stringaro A., Logozzi M., Travaglione S., et al. Activation of rho GTPases by cytotoxic necrotizing factor 1 induces macropinocytosis and scavenging activity in epithelial cells. Mol Biol Cell 2001, 12:2061-2073.
124. Lai Y., Lim D., Tan P.H., Leung T.K., Yip G.W., Bay B.H. Silencing the Metallothionein-2A gene induces entosis in adherent MCF-7 breast cancer cells. Anal Rec (Hoboken) 2010, 293:1685-1691.
125. Wan Q., Liu J., Zheng Z., Zhu H., Chu X., Dong Z., et al. Regulation of myosin activation during cell-cell contact formation by Par3-Lgl antagonism: entosis without matrix detachment. Mol Biol Cell 2012, 23:2076-2091.
126. Laster S.M., Wood J.G., Gooding L.R. Tumor necrosis factor can induce both apoptic and necrotic forms of cell lysis. J Immunol 1988, 141:2629-2634.
127. Cho Y.S., Challa S., Moquin D., Genga R., Ray T.D., Guildford M., et al. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell 2009, 137:1112-1123.
128. Hitomi J., Christofferson D.E., Ng A., Yao J., Degterev A., Xavier R.J., et al. Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway. Cell 2008, 135:1311-1323.
129. Zhang D.W., Shao J., Lin J., Zhang N., Lu B.J., Lin S.C., et al. RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science 2009, 325:332-336.
130. Degterev A., Huang Z., Boyce M., Li Y., Jagtap P., Mizushima N., et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol 2005, 1:112-119.
131. Zong W.X., Ditsworth D., Bauer D.E., Wang Z.Q., Thompson C.B. Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes Dev 2004, 18:1272-1282.
132. Bano D., Young K.W., Guerin C.J., Lefeuvre R., Rothwell N.J., Naldini L., et al. Cleavage of the plasma membrane Na+/Ca2+ exchanger in excitotoxicity. Cell 2005, 120:275-285.
133. Vercammen D., Brouckaert G., Denecker G., Van de Craen M., Declercq W., Fiers W., et al. Dual signaling of the Fas receptor: initiation of both apoptotic and necrotic cell death pathways. J Exp Med 1998, 188:919-930.
134. Holler N., Zaru R., Micheau O., Thome M., Attinger A., Valitutti S., et al. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol 2000, 1:489-495.
135. Boya P., Kroemer G. Lysosomal membrane permeabilization in cell death. Oncogene 2008, 27:6434-6451.
136. Kroemer G., Galluzzi L., Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev 2007, 87:99-163.
137. Goossens V., Stange G., Moens K., Pipeleers D., Grooten J. Regulation of tumor necrosis factor-induced, mitochondria- and reactive oxygen species-dependent cell death by the electron flux through the electron transport chain complex I. Antioxid Redox Signal 1999, 1:285-295.
138. Kim Y.S., Morgan M.J., Choksi S., Liu Z.G. TNF-induced activation of the Nox1 NADPH oxidase and its role in the induction of necrotic cell death. Molecular Cell 2007, 26:675-687.
139. Yazdanpanah B., Wiegmann K., Tchikov V., Krut O., Pongratz C., Schramm M., et al. Riboflavin kinase couples TNF receptor 1 to NADPH oxidase. Nature 2009, 460:1159-1163.
140. Monus Z., Laszlo F.A. Cyproterone acetate-promoted prevention of renal cortical necrosis following testosterone and vasopressin administration. Br J Exp Pathol 1979, 60:72-75.
141. Sun H.Z., Yang T.W., Zang W.J., Wu S.F. Dehydroepiandrosterone-induced proliferation of prostatic epithelial cell is mediated by NFKB via PI3K/AKT signaling pathway. J Endocrinol 2010, 204:311-318.
142. De Duve C., Wattiaux R. Functions of lysosomes. Annu Rev Physiol 1966, 28:435-492.
143. Yang Z., Klionsky D.J. Eaten alive: a history of macroautophagy. Nat Cell Biol 2010, 12:814-822.
144. Levine B., Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008, 132:27-42.
145. Montie H.L., Cho M.S., Holder L., Liu Y., Tsvetkov A.S., Finkbeiner S., et al. Cytoplasmic retention of polyglutamine-expanded androgen receptor ameliorates disease via autophagy in a mouse model of spinal and bulbar muscular atrophy. Hum Mol Genet 2009, 18:1937-1950.
146. Florey O., Kim S.E., Sandoval C.P., Haynes C.M., Overholtzer M. Autophagy machinery mediates macroendocytic processing and entotic cell death by targeting single membranes. Nat Cell Biol 2011, 13:1335-1343.
147. Levine B., Klionsky D.J. Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell 2004, 6:463-477.
148. Liu B., Cheng Y., Liu Q., Bao J.K., Yang J.M. Autophagic pathways as new targets for cancer drug development. Acta pharmacol Sin 2010, 31:1154-1164.
149. Liang C., Jung J.U. Autophagy genes as tumor suppressors. Curr Opin Cell Biol 2010, 22:226-233.
150. Parikh A., Childress C., Deitrick K., Lin Q., Rukstalis D., Yang W. Statin-induced autophagy by inhibition of geranylgeranyl biosynthesis in prostate cancer PC3 cells. Prostate 2010, 70:971-981.
151. Suh Y., Afaq F., Khan N., Johnson J.J., Khusro F.H., Mukhtar H. Fisetin induces autophagic cell death through suppression of mTOR signaling pathway in prostate cancer cells. Carcinogenesis 2010, 31:1424-1433.
152. Toepfer N., Childress C., Parikh A., Rukstalis D., Yang W. Atorvastatin induces autophagy in prostate cancer PC3 cells through activation of LC3 transcription. Cancer Biol Ther 2011, 12:691-699.
153. Kung H.J. Targeting tyrosine kinases and autophagy in prostate cancer. Horm Cancer 2011, 2:38-46.
154. Chuu C.P., Kokontis J.M., Hiipakka R.A., Fukuchi J., Lin H.P., Lin C.Y., et al. Androgen suppresses proliferation of castration-resistant LNCaP 104-R2 prostate cancer cells through androgen receptor, Skp2, and c-Myc. Cancer Sci 2011, 102:2022-2028.
155. Park M.T., Choi J.A., Kim M.J., Um H.D., Bae S., Kang C.M., et al. Suppression of extracellular signal-related kinase and activation of p38 MAPK are two critical events leading to caspase-8- and mitochondria-mediated cell death in phytosphingosine-treated human cancer cells. J Biol Chem 2003, 278:50624-50634.
156. Yang Z., Chang Y.J., Yu I.C., Yeh S., Wu C.C., Miyamoto H., et al. ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor. Nat Med 2007, 13:348-353.
157. Yamashita S., Lai K.P., Chuang K.L., Xu D., Miyamoto H., Tochigi T., et al. ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors. Neoplasia (New York, NY) 2012, 14:74-83.